Corcept Therapeutics Incorporated
CORT
Classifica tra le azioni
#1761
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Prezzo delle azioni
$112.72
Capitalizzazione di mercato
$12.18B
Variazione (1 giorno)
2.32%
Variazione (1 anno)
43.25%
Paese
US
Scambia Corcept Therapeutics Incorporated (CORT)
Categoria
Healthcare
Margine operativo per Corcept Therapeutics Incorporated (CORT)
Margine operativo al October 2026 TTM: 0.77%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Corcept Therapeutics Incorporated, il margine operativo attuale (TTM) è 0.77%. Alla fine del 2023, il margine operativo era 22.24%.
Storico del margine operativo per Corcept Therapeutics Incorporated da 2001 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | 0.77% | -96.21% |
| 2024 | 20.29% | -8.77% |
| 2023 | 22.24% | -20.66% |
| 2022 | 28.03% | -17.58% |
| 2021 | 34.01% | -6.13% |
| 2020 | 36.23% | -0.49% |
| 2019 | 36.41% | 2.22% |
| 2018 | 35.62% | 7.29% |
| 2017 | 33.20% | 165.18% |
| 2016 | 12.52% | -282.77% |
| 2015 | -6.85% | -93.41% |
| 2014 | -104.02% | -74.04% |
| 2013 | -400.66% | -63.47% |
| 2012 | -1,096.82% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | -100.00% |
| 2009 | -69,827.59% | 641.22% |
| 2008 | -9,420.57% | 270.82% |
| 2007 | -2,540.46% | -70.80% |
| 2006 | -8,701.36% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 62.34% | -19.04% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -61.35% |
HK
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.